

gofalu am ein gilydd, cydweithio, gwella bob amser caring for each other, working together, always improving

Rydym yn croesawu gohebiaeth yn y Gymraeg neu'r Saesneg. Atebir gohebiaeth Gymraeg yn y Gymraeg, ac ni fydd hyn yn arwain at oedi. We welcome correspondence in Welsh or English. Welsh language correspondence will be replied to in Welsh, and this will not lead to a delay.

Cais Rhyddid Gwybodaeth / Freedom of Information request Ein Cyf / Our Ref: 23-E-025

Please find below your completed questionnaire.

You asked:

Q1. Name and position of person answering the survey

Jagadish Nagaraj – Consultant Gastroenterology

Q2. Please enter the name of your Health Board

Swansea Bay University Health Board

Q3. Do you have a named person within the Health Board who is responsible for liver disease?

Yes

If yes, please move to Q3a

If no, please move to Q3b

Q3a If yes, please provide the name, title and email address of this person

Name: Jagadish Nagaraj

Title: Consultant Gastroenterology

Email address: Jagadish.Nagaraj@wales.nhs.uk

Q3b In the absence of a named contact for liver disease, please provide the name, title and email address of the person who should be contacted regarding liver health

Not applicable



- Q4. Do you have a commissioned pathway for a) the interpretation of abnormal liver blood tests? b) responding to liver disease more generally? Please could you attach/hyperlink any pathway documents to your response.
- ✓ Yes, pathways for both
- ✓ Yes, pathway for abnormal liver blood tests

If answer to any of these is yes, please move to Q5

If answer is no pathways for either, please move to Q7

Q5. Does it include an endorsed pathway for the management of abnormal liver blood tests that follows the BSG guidance?

Yes

Q6. Is liver fibrosis assessment part of your pathway? Yes

If yes, please move to Q6a

If no, please move to Q7

Q6a. Please indicate how fibrosis is assessed (Please tick all that apply):

- √ Fibroscan
- ✓ FIB-4
- ✓ NAFLD fibrosis score
- Q7. Do you have an additional pathway that proactively case-finds individuals who may be at high-risk of liver disease? Yes

If yes, please move to Q8

If no, please move to Q10

Q8. How does your pathway define individuals as high risk of liver disease? (Please tick all that apply)

- ✓ Diabetes
- ✓ Alcohol risk
- ✓ Obesity
- ✓ Obesity with other metabolic risk factors

Q9. How are these individuals identified? (Please tick all that apply)

- ✓ During the NHS Health Check
- ✓ Opportunistically during consultations

Q10: Does your contract with Drug and Alcohol Recovery Service providers include providing a liver disease diagnostic test?

✓ No

Q11: Does your contract with Weight Management Service providers include providing a liver disease diagnostic test?

✓ No

Q12. Does the Health Board monitor the breadth of adoption and efficacy of liver disease pathways in primary care in your area?

No

If yes, please move to Q13

If no, please move to Q14

Q13. Where are these statistics published?

Not applicable

Q14. Are you aware of current statistics relating to liver disease in your area and do you monitor these?

Yes

Q15. Would you be willing to share your pathway information with other Health Boards for best practice purposes?

Yes

Q16. Would you like to meet with the British Liver Trust and/or a local clinician to find out how you can improve liver disease in your area? (optional)

This information is not recorded by the Health Board. The right of access created by the Freedom of Information Act only applies to recorded information, the Health Board is under no obligation to divulge its unrecorded thoughts or opinions which your question is referring to. It is therefore not a valid request under FOIA.